Please assess the completion status of the following clinical trial:

Trial Title: RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria~Inclusion criteria (selected):~* Patients (18 years or older) scheduled to undergo a primary, unilateral, elect ive total knee replacement~* Written Informed Consent~Exclusion criteria~Exclusion criteria (selected):~* Patients with an excessive risk of bleeding, for example because of history of bleeding diathesis major surgery or trauma within the last 3 months history of haemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, arteriovenous (AV) malformation or aneurysm clinically relevant bleeding or gastric / duodenal ulcer within the last 6 months treatment with anticoagulants within 7 days prior to joint replacement surgery or anticipated need during the study treatment period thrombocytopenia.~* Active malignant disease or current cytostatic treatment~* Known severe renal insufficiency~* Liver disease expected to have any potential impact on survival, or elevated aspartate aminotransferase (AST) or alanine transaminase (ALT) \> 2x upper limit of normal~* Recent unstable cardiovascular disease or history of myocardial infarction within the last 3 months~* Pre-menopausal women who are pregnant or nursing, or are of child-bearing pote ntial and are not practising or do not plan to continue practising acceptable me thods of birth control~* Allergy to radio opaque contrast media or iodine, heparins (incl. heparin indu ced thrombocytopenia) or dabigatran~* Contraindications to enoxaparin~* Participation in a clinical trial during the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dabigatran etexilate 220 mg (Type: EXPERIMENTAL): 220 mg once daily
- dabigatran etexilate 150 mg (Type: EXPERIMENTAL): 150 mg once daily
- enoxaparin (Type: ACTIVE_COMPARATOR): 40 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).